Genicular Nerve Block in Chronic Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2024-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate whether genicular nerve block (GNB) is effective in reducing pain in patients with knee osteoarthritis. It will also assess the comparative efficacy of different injection protocols.

The main questions it aims to answer are:

Does genicular nerve block with corticosteroid and local anesthetic provide superior pain relief compared with local anesthetic alone or placebo?

Are there differences in clinical outcomes between the three treatment groups?

Researchers will compare three groups:

GNB with corticosteroid plus local anesthetic

GNB with local anesthetic alone

Sham procedure with saline (placebo control)

Participants will:

Receive the assigned injection protocol in accordance with their group

Be evaluated at baseline and scheduled follow-up visits for pain intensity and functional status

Report their pain scores and functional limitations using standardized assessment tools

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ecoguided Genicular Nerve Block

NCT06619080

Osteoarthritis, Knee/Rehabilitation

COMPLETED NA

Genicular Nerve Block in Rheuamtoid Arthritis

NCT04361513

Pain Joint Function Disorder Inflammation

COMPLETED PHASE4

The Effect of Different Intra-articular Injections Primary Gonarthrosis

NCT05291793

Gonarthrosis; Primary

COMPLETED NA

Genicular Nerve Block in Juvenile Idiopathic Arthritis

NCT04687930

Juvenile Idiopathic Arthritis Persistent Knee Arthritis no Intra-articular Injection in the Last 3 Months +1 more

COMPLETED PHASE4

Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee

NCT02845271

Osteoarthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gonarthrosis; Primary Genicular Nerve Block Gonarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

genicular nerve block with local anesthetic

Group 1 (GNB with local anesthetic only): Patients received a genicular nerve block (GNB) with 6 mL of 2% prilocaine and participated in a knee exercise program.

Group Type ACTIVE_COMPARATOR

Genicular nerve block with prilocaine

Intervention Type DRUG

ultrasound guided genicular nerve block (GNB) injecting 6 mL of 2% prilocaine to the genicular nerves

genicular nerve block with local anesthetic and corticosteroid

Group 2 (GNB with local anesthetic and corticosteroid): Patients received GNB with 5 mL of 2% prilocaine in combination with 1 mL/40 mg of triamcinolone and followed the same exercise regimen.

Group Type ACTIVE_COMPARATOR

genicular nerve block with prilocaine and triamcinolone

Intervention Type DRUG

ultrasound guided genicular nerve block (GNB) injecting 5 mL of 2% prilocaine in combination with 1 mL/40 mg of triamcinolone to the genicular nerves

sham injection with saline

Group 3 (Control group): Patients received a placebo injection (6 mL of 0.9% saline) with the knee exercise program.

Group Type SHAM_COMPARATOR

Sham injection

Intervention Type DRUG

placebo injection using 6 mL of 0.9% saline to knee region other than genicular nerves

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genicular nerve block with prilocaine

ultrasound guided genicular nerve block (GNB) injecting 6 mL of 2% prilocaine to the genicular nerves

Intervention Type DRUG

genicular nerve block with prilocaine and triamcinolone

ultrasound guided genicular nerve block (GNB) injecting 5 mL of 2% prilocaine in combination with 1 mL/40 mg of triamcinolone to the genicular nerves

Intervention Type DRUG

Sham injection

placebo injection using 6 mL of 0.9% saline to knee region other than genicular nerves

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

group 1 group 2 group 3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 45 and 75
* diagnosed with knee osteoarthritis (OA) according to the American College of Rheumatology (ACR) criteria
* possessing a Kellgren-Lawrence radiological grade of 2-3

Exclusion Criteria

* any joint injection to the target knee in the past 3 months
* physical therapy for the target knee within the last 3 months
* previous knee surgery
* inflammatory rheumatic diseases
* active lumbar radiculopathy on the same side
* neurological disorders (e.g., Alzheimer's or dementia)
* uncontrolled cardiopulmonary diseases
* pregnancy or lactation
* obesity (body mass index \[BMI\] \>35)
* presence of a pacemaker
* active malignancy

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No